Repare Therapeutics Files 8-K on Material Agreement & Asset Deal
| Field | Detail |
|---|---|
| Company | Repare Therapeutics Inc. |
| Form Type | 8-K |
| Filed Date | Dec 29, 2025 |
| Risk Level | medium |
| Pages | 9 |
| Reading Time | 11 min |
| Key Dollar Amounts | $30,000,000, $22,000,000, $3,000,000, $5,000,000, $250,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, acquisition-disposition, regulation-fd
TL;DR
Repare Therapeutics filed an 8-K on 12/23/25 for a material agreement and asset deal.
AI Summary
On December 23, 2025, Repare Therapeutics Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers the completion of an acquisition or disposition of assets, a Regulation FD disclosure, and other events, along with financial statements and exhibits. The company is incorporated in Quebec and its principal executive offices are located at 7171 Frederick-Banting, Building 2, Suite 270, St-Laurent, Quebec, Canada.
Why It Matters
This 8-K filing indicates significant corporate activity for Repare Therapeutics, potentially involving new agreements or changes in asset ownership that could impact its business operations and financial standing.
Risk Assessment
Risk Level: medium — Material definitive agreements and asset dispositions can introduce significant financial and operational risks or opportunities, requiring careful investor scrutiny.
Key Players & Entities
- Repare Therapeutics Inc. (company) — Registrant
- December 23, 2025 (date) — Date of earliest event reported
- Quebec (location) — State of Incorporation
- 7171 Frederick-Banting, Building 2, Suite 270 (address) — Principal Executive Offices
- St-Laurent, Quebec, Canada (location) — City, Province, Country of Principal Executive Offices
FAQ
What type of material definitive agreement was entered into by Repare Therapeutics?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on or before December 23, 2025.
What was the nature of the acquisition or disposition of assets?
The filing indicates the completion of an acquisition or disposition of assets, but provides no details on the specific assets or the transaction.
What is the significance of the Regulation FD Disclosure mentioned in the filing?
A Regulation FD Disclosure item suggests that material non-public information may have been disclosed, requiring the company to make that information public.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on December 23, 2025.
Where are Repare Therapeutics' principal executive offices located?
Repare Therapeutics' principal executive offices are located at 7171 Frederick-Banting, Building 2, Suite 270, St-Laurent, Quebec, Canada.
Filing Stats: 2,637 words · 11 min read · ~9 pages · Grade level 15 · Accepted 2025-12-29 07:00:57
Key Financial Figures
- $30,000,000 — ny an aggregate purchase price of up to $30,000,000 in cash, consisting of (i) a $22,000,00
- $22,000,000 — 30,000,000 in cash, consisting of (i) a $22,000,000 payment due to the Company no later tha
- $3,000,000 — , 2025, (ii) a holdback amount of up to $3,000,000 that may become payable after one year
- $5,000,000 — he Asset Purchase Agreement and (iii) a $5,000,000 transfer completion payment (the "Trans
- $250,000 — , in exchange for a one-time payment of $250,000. Item7.01 Regulation FD Disclosure.
- $2.20 — ceive a cash payment of approximately US$2.20 per Common Share at the Arrangement Clo
Filing Documents
- d32279d8k.htm (8-K) — 46KB
- d32279dex21.htm (EX-2.1) — 309KB
- d32279dex101.htm (EX-10.1) — 20KB
- d32279dex991.htm (EX-99.1) — 15KB
- g32279dsp58.jpg (GRAPHIC) — 6KB
- g32279g1227023940242.jpg (GRAPHIC) — 3KB
- 0001193125-25-332236.txt ( ) — 610KB
- rptx-20251223.xsd (EX-101.SCH) — 2KB
- rptx-20251223_lab.xml (EX-101.LAB) — 18KB
- rptx-20251223_pre.xml (EX-101.PRE) — 11KB
- d32279d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 2.1* Asset Purchase Agreement, dated as of December 23, 2025, by and between Repare Therapeutics Inc. and Gilead Sciences, Inc. 10.1 Consent to Assignment by and between Repare Therapeutics Inc. and New York University. 99.1 Press Release dated December 24, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Schedules and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant will furnish a supplemental copy of any omitted schedule or similar attachment to the SEC upon request. Certain portions of this exhibit (indicated by asterisks) have been omitted because they are not material and would likely cause competitive harm to Repare Therapeutics Inc. if publicly disclosed.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REPARE THERAPEUTICS INC. By: /s/ Steve Forte Steve Forte President, Chief Executive Officer and Chief Financial Officer Dated: December 29, 2025